The EMA approved Moderna's mRNA COVID-19 and flu vaccine, but US political battles and funding cuts threaten the future of mRNA vaccine innovation. Talha Burki reports.
The COVID pandemic ushered mRNA vaccines into the spotlight, and the technology has even greater potential. Here’s what to ...
BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other ...
Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice. The ...
The Food and Drug Administration has refused to review Moderna's application for its seasonal flu vaccine, the company announced on Feb. 10, marking the latest setback for the development of ...
US Government cuts to mRNA vaccine research could set technological advances, reduce access to therapies, and raise their costs.mRNA vaccines are credited with helping to end the COVID-19 pandemic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results